Review abstract
Nature Biotechnology 25, 1444 - 1454 (2007)
Published online: 7 December 2007 | doi:10.1038/nbt1367
Genetic therapies against HIV
John J Rossi1, Carl H June2 & Donald B Kohn3
Abstract
Highly active antiretroviral therapy prolongs the life of HIV-infected individuals, but it requires lifelong treatment and results in cumulative toxicities and viral-escape mutants. Gene therapy offers the promise of preventing progressive HIV infection by sustained interference with viral replication in the absence of chronic chemotherapy. Gene-targeting strategies are being developed with RNA-based agents, such as ribozymes, antisense, RNA aptamers and small interfering RNA, and protein-based agents, such as the mutant HIV Rev protein M10, fusion inhibitors and zinc-finger nucleases. Recent advances in T-cell–based strategies include gene-modified HIV-resistant T cells, lentiviral gene delivery, CD8+ T cells, T bodies and engineered T-cell receptors. HIV-resistant hematopoietic stem cells have the potential to protect all cell types susceptible to HIV infection. The emergence of viral resistance can be addressed by therapies that use combinations of genetic agents and that inhibit both viral and host targets. Many of these strategies are being tested in ongoing and planned clinical trials.
- Division of Molecular Biology, Graduate School of Biological Sciences, Beckman Research Institute of the City of Hope, Duarte, California 91010, USA.
- The Abramson Family Cancer Research Institute and Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
- Division of Research, Immunology/B.M.T., Childrens Hospital Los Angeles, Departments of Pediatrics and Molecular Microbiology & Immunology, University of Southern California Keck School of Medicine, Los Angeles, California 90027, USA.
Correspondence to: John J Rossi1 e-mail: jrossi@coh.org.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Lentiviral vectors ready for prime-timeNature Biotechnology News and Views (01 Jan 2007)
Lentiviral vectors ready for prime-timeNature Biotechnology News and Views (01 Jan 2007)
See all 3 matches for News And ViewsRESEARCH
Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34 + cellsNature Medicine Article (01 Mar 2009)
Foamy Virus Vectors Expressing Anti-HIV Transgenes Efficiently Block HIV-1 ReplicationMolecular Therapy Original Article
See all 49 matches for Research

